GlassScriptPhysician profile
Ronald J Ostrom
NPI 1730169855
$2,709.18
in general payments reported to CMS, 2019-2025
14 companies · $946 in 2025
The $946 reported for 2025 was more than what 95% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $258 · 2021: $12.54 · 2022: $28.96 · 2023: $127 · 2024: $979 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,063 · Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,062.52 |
| Food and Beverage | $989.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $945.97 | 2025 | Spinejack, Optablate, Mild Device Kit |
| Medtronic, INC. | $847.49 | 2024 | Intellis Adaptivestim, Accurian, Kyphon Express II Kyphopak Tray |
| Abiomed | $444.84 | 2019-2020 | |
| Allergan, INC. | $142.98 | 2019-2020 | |
| Abbott Laboratories | $92.60 | 2024 | Proclaim |
| Lilly USA, LLC | $73.43 | 2021-2024 | Mounjaro |
| Abbvie INC. | $32.52 | 2023 | |
| Janssen Pharmaceuticals, INC | $27.79 | 2020 | |
| Glaxosmithkline, LLC. | $27.02 | 2022-2023 | Shingrix |
| Purdue Pharma L.P. | $20.94 | 2024 | Nalmefene Hydrochloride |
| Exact Sciences Corporation | $19.21 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $17.77 | 2023 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $16.62 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$366,784.63 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Ostrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.